Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean xia chen ai (61 results)?
Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer.
Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A. Rugo HS, et al. Oncologist. 2023 Oct 3;28(10):866-874. doi: 10.1093/oncolo/oyad209. Oncologist. 2023. PMID: 37487056 Free PMC article.
RESULTS: Of 270 eligible patients, 127 (median age 64 years) were treated with palbociclib + AI, and 143 (median age 68 years) were treated with an AI. Median follow-up was 24.0 months for palbociclib + AI and 18.2 months for AI-treated patients. ...Me …
RESULTS: Of 270 eligible patients, 127 (median age 64 years) were treated with palbociclib + AI, and 143 (median age 68 years) were t …
Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer.
Engel-Nitz NM, Johnson MG, Johnson MP, Cha-Silva AS, Kurosky SK, Liu X. Engel-Nitz NM, et al. Patient Prefer Adherence. 2023 Apr 18;17:1049-1062. doi: 10.2147/PPA.S401480. eCollection 2023. Patient Prefer Adherence. 2023. PMID: 37096162 Free PMC article.
Adult patients with mBC who had continuous enrollment 12 months prior to mBC diagnosis and initiated first-line palbociclib with aromatase inhibitor (AI) or fulvestrant between 02/03/2015 and 12/31/2019 were included. ...RESULTS: Patients (n = 1066) with a mean age of 66 y …
Adult patients with mBC who had continuous enrollment 12 months prior to mBC diagnosis and initiated first-line palbociclib with aromatase i …
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
Brufsky A, Liu X, Li B, McRoy L, Layman RM. Brufsky A, et al. Target Oncol. 2021 Sep;16(5):601-611. doi: 10.1007/s11523-021-00826-1. Epub 2021 Aug 2. Target Oncol. 2021. PMID: 34338965 Free PMC article.
BACKGROUND: Limited information exists regarding tumor response to palbociclib plus an aromatase inhibitor (AI) versus AI alone in real-world practice. OBJECTIVE: To evaluate the real-world tumor response of palbociclib plus letrozole (PAL+LET) versus LET alone as f …
BACKGROUND: Limited information exists regarding tumor response to palbociclib plus an aromatase inhibitor (AI) versus AI alon …
Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling.
Maculaitis MC, Liu X, Will O, Hanson M, McRoy L, Berk A, Crastnopol M. Maculaitis MC, et al. Patient Prefer Adherence. 2020 Nov 5;14:2201-2214. doi: 10.2147/PPA.S254934. eCollection 2020. Patient Prefer Adherence. 2020. PMID: 33177814 Free PMC article.
PURPOSE: To understand and compare preferences for dosing- and toxicity-related attributes associated with selective cyclin-dependent 4/6 kinase inhibitors regimens among US oncologists and patients. MATERIALS AND METHODS: Oncologists and patients with mBC participated in …
PURPOSE: To understand and compare preferences for dosing- and toxicity-related attributes associated with selective cyclin-dependent 4/6 ki …